With over 0.47 million 60 Degrees Pharmaceuticals Inc (SXTP) shares trading Friday and a closing price of $0.90 on the day, the dollar volume was approximately $0.42 million. Currently, there are 5.78M common shares owned by the public and among those 3.91M shares have been available to trade.
Fidelity Extended Market Index Fu owns 7089.0 shares of the company’s stock, all valued at over $4395.0.
Shares of 60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) opened at $0.91, down -$0.19 from a prior closing price of $1.10. However, the script later moved the day high at 1.0800, down -18.03%. The company’s stock has a 5-day price change of 29.00% and 34.58% over the past three months. It has a 12-month low price of $0.51 and touched a high of $8.65 over the same period. SXTP has an average intraday trading volume of 150.07K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 23.88%, 30.80%, and -25.41% respectively.
Institutional ownership of 60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) shares accounts for 11.16% of the company’s 5.78M shares outstanding. Mutual fund holders own 11.04%, while other institutional holders and individual stakeholders account for 19.11% and 0.12% respectively.
It has a market capitalization of $5.23M. Price movements for the stock have been influenced by the stock’s volatility, which stands at 35.20% over the week and 15.62% over the month.
Analysts forecast that 60 Degrees Pharmaceuticals Inc (SXTP) will achieve an EPS of -$0.2 for the current quarter, -$0.18 for the next quarter and -$0.52 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.27 while analysts give the company a high EPS estimate of -$0.14.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate 60 Degrees Pharmaceuticals Inc (SXTP) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 1 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
